HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the united states: A cost-effectiveness analysis

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Long, Elisa F ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE TRANSMISSION; FEMALE; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MALE; MALE HOMOSEXUAL; MASS SCREENING; NUCLEIC ACID AMPLIFICATION; POPULATION RESEARCH; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; UNITED STATES; ACUTE DISEASE; BEHAVIOR; BIOLOGICAL MODEL; ECONOMICS; HOMOSEXUALITY; MIDDLE AGED; STATISTICS; TIME;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BEHAVIOR; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; IMMUNOASSAY; MALE; MASS SCREENING; MIDDLE AGED; MODELS, BIOLOGICAL; NUCLEIC ACID AMPLIFICATION TECHNIQUES; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 81155128340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027625     Document Type: Article

References (49)

1. Hall HI, Song R, Rhodes P, Prejean J, An Q, et al. (2008) Estimation of HIV incidence in the United States. JAMA 300: 520-529.
2. Pinkerton SD, (2007) How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS 21: 1625-1629.
3. Prabhu VS, Hutchinson AB, Farnham PG, Sansom SL, (2009) Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS 23: 1792-1794.
4. Miller WC, Rosenberg NE, Rutstein SE, Powers KA, (2010) Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS 5: 277-282.
5. Hollingsworth TD, Anderson RM, Fraser C, (2008) HIV-1 transmission, by stage of infection. J Infect Dis 198: 687-693.
6. Patel P, Mackellar D, Simmons P, Uniyal A, Gallagher K, et al. (2010) Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Arch Intern Med 170: 66-74.
7. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871-1879.
8. Fox J, White PJ, Macdonald N, Weber J, McClure M, et al. (2009) Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med 10: 432-438.
9. Steward WT, Remien RH, Higgins JA, Dubrow R, Pinkerton SD, et al. (2009) Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav 13: 1054-1060.
10. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, et al. (2002) Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 16: 1119-1129.
11. Patel P, Klausner JD, Bacon OM, Liska S, Taylor M, et al. (2006) Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr 42: 75-79.
12. Pilcher CD, Fiscus SA, Nguyen TQ, Foust E, Wolf L, et al. (2005) Detection of acute infections during HIV testing in North Carolina. N Engl J Med 352: 1873-1883.
13. Pilcher CD, McPherson JT, Leone PA, Smurzynski M, Owen-O'Dowd J, et al. (2002) Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA 288: 216-221.
14. Priddy FH, Pilcher CD, Moore RH, Tambe P, Park MN, et al. (2007) Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr 44: 196-202.
15. Quinn TC, Brookmeyer R, Kline R, Shepherd M, Paranjape R, et al. (2000) Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS 14: 2751-2757.
16. Sherlock M, Zetola NM, Klausner JD, (2007) Routine detection of acute HIV infection through RNA pooling: survey of current practice in the United States. Sex Transm Dis 34: 314-316.
17. Hutchinson AB, Patel P, Sansom SL, Farnham PG, Sullivan TJ, et al. (2010) Cost-effectiveness of pooled nucleic acid amplification testing for acute HIV infection after third-generation HIV antibody screening and rapid testing in the United States: a comparison of three public health settings. PLoS Med 7: e1000342.
18. Eshleman SH, Khaki L, Laeyendecker O, Piwowar-Manning E, Johnson-Lewis L, et al. (2009) Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr 52: 121-124.
19. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, et al. (2006) Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 55: 1-17.
20. Long EF, Brandeau ML, Owens DK, (2010) The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 153: 778-789.
21. Long EF, Brandeau ML, Owens DK, (2009) Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine 27: 5402-5410.
22. CensusScope (2000) United States Age Distribution. Available at: http://www.censusscope.org/us/chart_age.html. Accessed 6 July 2011.
23. Centers for Disease Control and Prevention (CDC) (2010) HIV and AIDS in the United States. Available at: http://www.cdc.gov/hiv/resources/factsheets/us.htm. Accessed 6 July 2011.
24. Centers for Disease Control and Prevention (CDC) (2010) HIV and AIDS among Gay and Bisexual Men. Available at: http://www.cdc.gov/nchhstp/newsroom/docs/FastFacts-MSM-FINAL508COMP.pdf. Accessed 6 July 2011.
25. Centers for Disease Control and Prevention (CDC) (2008) Estimates of New HIV Infections in the United States. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/incidence.htm. Accessed 6 July 2011.
26. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, et al. (2003) Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health 80: 137-146.
27. Friedman SR, Tempalski B, Cooper H, Perlis T, Keem M, et al. (2004) Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health 81: 377-400.
28. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2010) Report on the Global AIDS Epidemic. Geneva, Switzerland.
29. Abbas UL, Anderson RM, Mellors JW, (2006) Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr 41: 632-641.
30. Cohen MS, Gay C, Kashuba ADM, Blower S, Paxton L, (2007) Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 146: 591-601.
31. Kamb ML, Fishbein M, Douglas JM, Rhodes F, Rogers J, et al. (1998) Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 280: 1161-1167.
32. McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, et al. (2007) The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis 44: 1115-1122.
33. National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group (1998) The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. Science 280: 1889-1894.
34. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.
35. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, et al. (2005) Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352: 570-585.
36. Pilcher CD, Tien HC, Eron JJ, Vernazza PL, Leu SY, et al. (2004) Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 189: 1785-1792.
37. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
38. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, et al. (2005) Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191: 1403-1409.
39. Westreich DJ, Hudgens MG, Fiscus SA, Pilcher CD, (2008) Optimizing screening for acute human immunodeficiency virus infection with pooled nucleic acid amplification tests. J Clin Microbiol 46: 1785-1792.
40. Gold MR, Siegel JE, Russell LB, Weinstein MC, (1996) Cost-Effectiveness in Health and Medicine. New York Oxford University Press.
41. Hollingsworth TD, Anderson RM, Fraser C, (2006) Has the role of primary HIV been overstated? 13th Conference on Retroviruses and Opportunistic Infections Abstract # 913.
42. Paltiel AD, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, et al. (2006) Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 145: 797-806.
43. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR, Losina E, et al. (2005) Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med 352: 586-595.
44. Centers for Disease Control and Prevention (CDC) (2008) Persons tested for HIV-United States, 2006. MMWR Morb Mortal Wkly Rep 57: 845-849.
45. Marks G, Crepaz N, Senterfitt JW, Janssen RS, (2005) Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 39: 446-453.
46. Coco A, (2005) The cost-effectiveness of expanded testing for primary HIV infection. Ann Fam Med 3: 391-399.
47. Centers for Medicaid and Medicare Services (2009) Medicaid Fee Schedule. Available at: http://www.med-quest.us/PDFs/Provider%20Memos/Medicaid%20Fee%20Schedule.pdf. Accessed 6 July 2011.
48. Elbeik T, Charlebois E, Nassos P, Kahn J, Hecht F, et al. (2000) Quantitative and cost comparison of ultrasensitive human immunodeficiency virus type 1 RNA viral load assays: Bayer bDNA quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor monitor version 1.5. J Clin Microbiol 38: 1113-1120.
49. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, et al. (2001) The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 344: 824-831.